Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity. The investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase 1: Circulating adipocyte-derived extracellular vesicles (Ad-EVs)
Timeframe: Circulating Ad-EVs will measured during Phase 1 visit 2 which is ~2 weeks from their respective start date.
Phase 2: Circulating adipocyte-derived extracellular vesicles (Ad-EVs)
Timeframe: Circulating Ad-EVs will be measured during Phase 2 visit 15 which is ~17 weeks from their respective start date.
Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh)
Timeframe: FBF response to ACh will be measured during Phase 1 and the participant's visit 2 which is ~ 2 weeks from their respective start date.
Phase 2: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh)
Timeframe: FBF response to ACh will be measured during Phase 2 and the participant's visit 15 which is ~17 weeks from their respective start date.
Phase 1: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP)
Timeframe: FBF response to NTP will be measured during Phase 1 and the participant's visit 2 which is ~ 2 weeks from their respective start date.
Phase 2: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP)
Timeframe: FBF response to NTP will be measured during Phase 2 and the participant's visit 15 which is ~17 weeks from their respective start date.